OpenAI-backed Red Queen Bio raises $36M for AI antibody drugs
Red Queen Bio, a startup backed by OpenAI, has raised $36 million to develop antibody drugs using artificial intelligence. The company focuses on designing treatments for novel pathogens, with a specific emphasis on preparing for threats posed by AI-enabled bioweapons.
Key points
- Red Queen Bio raised $36 million in funding.
- The startup is backed by OpenAI.
- It uses AI to design antibody drugs against novel pathogens and AI-enabled bioweapons.
The startup's approach involves using AI to anticipate and create defenses against pathogens that future AI systems might generate. This proactive strategy aims to stay ahead of potential biosecurity risks by developing medical countermeasures before such threats become widespread.
The funding highlights a growing intersection between AI capabilities and biosecurity, where companies are leveraging machine learning not just for discovery, but for defensive biological applications. OpenAI's involvement signals industry interest in addressing the dual-use nature of advanced AI in biology.
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Business & Funding
All →- OpenAI raises $11B at $1.25T valuation, Bloomberg reports · 18 src
- WWT to secure £225m in European compute for AI startups · 1 src
- Nvidia stock fell 9.26% on Thursday, November 5, to $181.60 · 3 src
- Sand.ai raises $200M Series A+ to reach $1B valuation · 1 src
- AMD CEO says company is data‑center first amid soaring GPU prices · 1 src
Comments
via GitHub Discussions